Tricyclic PGD2 Metabolite Methyl Ester Synthesis With Catalytic Step Merging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing tricyclic prostaglandin D2 metabolite methyl ester are complex and inefficient, requiring numerous steps and low overall yields, limiting their availability for clinical assays.
Innovation Solution
A concise synthesis method involving transition metal-catalyzed transformations, including nickel-catalyzed dicarbofunctionalization, palladium-catalyzed carbonylative spirolactonization, and Z-selective cross metathesis, to efficiently produce tricyclic prostaglandin D2 metabolite methyl ester from readily available starting materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional synthesis methods are used, then the synthesis can be performed with standard procedures, but the number of steps increases and overall yield decreases
Solution Approach 1:
The patent employs transition metal catalysis (nickel, palladium, ruthenium) to change the reaction parameters and mechanism, enabling dicarbofunctionalization, carbonylative spirolactonization, and Z-selective cross metathesis reactions that significantly improve overall yield while reducing synthesis steps compared to conventional methods
Solution Approach 2:
The patent uses transition metal catalysts as intermediaries to facilitate complex transformations. Specifically, nickel catalysts mediate dicarbofunctionalization, palladium catalysts enable carbonylative spirolactonization, and ruthenium catalysts achieve Z-selective cross metathesis, allowing efficient synthesis through catalytic cycles rather than stepwise conventional reactions
2Manufacturing precision
If multi-step synthesis is used, then complex molecular structures can be formed, but the synthesis time and complexity increase
Solution Approach 1:
The patent merges multiple bond-forming events into single catalytic steps. The nickel-catalyzed dicarbofunctionalization forms two C-C bonds simultaneously, and the palladium-catalyzed carbonylative spirolactonization forms both the lactone ring and carbonyl group in one step, dramatically reducing synthesis time while maintaining molecular complexity
Solution Approach 2:
The patent performs preliminary catalytic transformations on readily available starting materials to install key functional groups and stereocenters early in the synthesis. The Z-selective cross metathesis establishes the critical (Z)-configuration early, which then directs subsequent reactions, reducing overall synthesis time while ensuring molecular precision
3Ease of operation
If traditional cyclization methods are used, then the reaction can proceed with simple conditions, but the yield and stereoselectivity are insufficient
Solution Approach 1:
The patent changes the reaction parameters by introducing transition metal catalysts that enable stereoselective transformations under relatively simple conditions. The ruthenium-catalyzed Z-selective cross metathesis achieves high stereoselectivity for the (Z)-isomer under mild conditions, and the palladium-catalyzed carbonylative spirolactonization proceeds with high yield and sterecontrol, improving both ease of operation and manufacturing precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high yields of up to 75 mg of tricyclic prostaglandin D2 metabolite methyl ester, overcoming the limitations of previous methods by providing a scalable and stereoselective synthesis.
Implementation Method 1
nickel-catalyzed dicarbofunctionalization
Implementation Method 2
palladium-catalyzed carbonylative spirolactonization
Implementation Method 3
Z-selective cross metathesis
Data Source
AI summary
Methods for the synthesis of a tricyclic-prostaglandin D2 metabolite methyl ester or a pharmaceutically acceptable salt thereof.